Luminex Acquires PCR System Developer
With this acquisition, Luminex can now offer a proprietary instrument for its PCR chemistries. A Luminex spokesperson told IBO that the system will be launched in 2013 and that pricing has not yet been determined. The GenturaDx system automates lysis, purification, amplification, confirmation and interpretation, according to GenturaDx’s website. The system allows for batch or single sample capacity, is scalable for 1 to 48 tests and houses two six-color thermal cyclers.
Austin, TX 7/9/12—Luminex has definitely agreed to acquire molecular diagnostics firm GenturaDx for $50 million in cash, subject to working-capital reconciliation and potential contingent consideration. GenturaDx is in late-stage development of an integrated, automated, real-time PCR system that utilizes a single-use cassette. Luminex plans to integrate its MultiCode-RTx chemistry with the instrument and commercialize assays for the system by early 2014. “This acquisition accelerates the development of integrated sample-processing capabilities for our technology, and aligns with our mission to reduce health care costs and improve clinical outcomes by providing innovative and affordable solutions to today’s clinical laboratories,” stated Luminex President and CEO Patrick J. Balthrop. The acquisition is expected to be dilutive to Luminex EPS in 2012 and to add $6 million to 2012 operating expenses.
